Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$47.39 - $80.2 $9.19 Million - $15.6 Million
-194,000 Reduced 44.7%
240,000 $12.7 Million
Q1 2024

May 15, 2024

BUY
$17.4 - $94.5 $5.64 Million - $30.6 Million
324,000 Added 294.55%
434,000 $35.6 Million
Q4 2023

Feb 14, 2024

BUY
$9.24 - $19.64 $739,200 - $1.57 Million
80,000 Added 266.67%
110,000 $2.05 Million
Q3 2023

Nov 14, 2023

SELL
$10.92 - $16.0 $764,400 - $1.12 Million
-70,000 Reduced 70.0%
30,000 $332,000
Q1 2023

May 15, 2023

BUY
$8.08 - $17.33 $808,000 - $1.73 Million
100,000 New
100,000 $1.66 Million
Q1 2021

May 17, 2021

SELL
$5.74 - $9.67 $287,000 - $483,500
-50,000 Closed
0 $0
Q4 2019

Feb 13, 2020

SELL
$6.38 - $8.73 $1.12 Million - $1.53 Million
-175,000 Reduced 77.78%
50,000 $402,000
Q3 2019

Nov 14, 2019

BUY
$6.55 - $8.6 $1.47 Million - $1.94 Million
225,000 New
225,000 $1.55 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.59B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.